What is DENTSPLY SIRONA Inc.'s earnings per share (EPS)?

DENTSPLY SIRONA Inc. (XRAY) reported diluted earnings per share of -$3.00 for fiscal year 2025. This represents a 33.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

DENTSPLY SIRONA Inc. (XRAY) Financials

XRAY

Trailing 12 months to June 30, 2026

Revenue $3.6B -0.8% YoY

Net Income -$546.0M +42.5% YoY

EPS (Diluted) -$2.74 +41.8% YoY

Free Cash Flow $143.0M +3.6% YoY

Market Cap $1.7B as of Oct 5, 2026

Price / Sales 0.5x on $3.6B revenue, trailing 12 months to June 30, 2026

Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to June 30, 2026

Price / Book 1.3x on $1.4B equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 5, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 6, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the XRAY SEC filings page.

DENTSPLY SIRONA Inc. (XRAY) reported $3.6B in revenue over the twelve months to Jun 30, 2026, down 0.8% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI XRAY FY2025 2026-10-03

Shrinking sales and thinner margins have left a still-cash-generative business with less financial cushion and heavier leverage.

FY2025 free cash flow was only $104M versus dividends of $128M, so shareholder distributions exceeded internally generated cash. Meanwhile, debt-to-equity rose from 0.8x in FY2024 to 1.5x, indicating that financing support shifted more toward creditors as equity contracted.

Revenue fell from $4.23B in FY2021 to $3.68B in FY2025, indicating the company is operating on a smaller sales base. Gross margin also narrowed from 55.5% to 50.0%, so weaker economics were not merely a volume issue.

Operating cash flow was $235M against a net loss of $598M in FY2025, showing that reported earnings were heavily affected by non-cash or timing items. Cash generation nevertheless fell from $461M in FY2024 to $235M, meaning cash conversion weakened even as the reported loss narrowed.

Financial Health Signals

Financial Health Score 30/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of DENTSPLY SIRONA Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

DENTSPLY SIRONA Inc. has an operating margin of -11.5%, meaning the company loses $11 on every $100 of revenue. This results in a profitability score of 18/100. This is up from -23.2% the prior year.

Growth

DENTSPLY SIRONA Inc.'s revenue declined 3.0% year-over-year, from $3.8B to $3.7B. This contraction results in a growth score of 19/100.

Leverage

DENTSPLY SIRONA Inc. has a moderate D/E ratio of 1.50. This balance of debt and equity financing earns a leverage score of 38/100.

Liquidity

DENTSPLY SIRONA Inc.'s current ratio of 1.51 indicates adequate short-term liquidity, earning a score of 41/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

DENTSPLY SIRONA Inc. has a free cash flow margin of 2.8%, earning a moderate score of 44/100. The company generates positive cash flow after capital investments, but with room for improvement.

Returns

DENTSPLY SIRONA Inc. posts a -44.7% return on equity (ROE), meaning it loses $45 for every $100 of shareholders' equity. This results in a returns score of 19/100. This is up from -46.9% the prior year.

Altman Z-Score Distress

0.42

DENTSPLY SIRONA Inc. scores 0.42, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($1.7B) relative to total liabilities ($4.1B). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Neutral

5/9

DENTSPLY SIRONA Inc. passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Mixed

N/A

DENTSPLY SIRONA Inc. reported a net loss of $598.0M while generating $235.0M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

DENTSPLY SIRONA Inc. reported an operating loss of $422.0M against $88.0M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$898.0M

YoY-4.1%

QoQ+2.0%

5Y CAGR-3.3%

10Y CAGR-1.3%

DENTSPLY SIRONA Inc. generated $898.0M in revenue in Q2 2026. This represents a decrease of 4.1% from the same quarter a year earlier. Against the prior quarter it is up 2.0%.

EBITDA

$167.0M

YoY+517.5%

QoQ+279.5%

DENTSPLY SIRONA Inc.'s EBITDA was $167.0M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 517.5% from the same quarter a year earlier. Against the prior quarter it is up 279.5%.

Net Income

$37.0M

YoY+182.2%

QoQ+470.0%

5Y CAGR-17.4%

10Y CAGR-9.9%

DENTSPLY SIRONA Inc. reported $37.0M in net income in Q2 2026. This represents an increase of 182.2% from the same quarter a year earlier. Against the prior quarter it is up 470.0%.

EPS (Diluted)

$0.18

YoY+181.8%

QoQ+460.0%

5Y CAGR-16.0%

10Y CAGR-8.6%

DENTSPLY SIRONA Inc. earned $0.18 per diluted share (EPS) in Q2 2026. This represents an increase of 181.8% from the same quarter a year earlier. Against the prior quarter it is up 460.0%.

Cash & Balance Sheet

Free Cash Flow

$55.0M

YoY+243.8%

QoQ+558.3%

10Y CAGR-10.2%

DENTSPLY SIRONA Inc. generated $55.0M in free cash flow in Q2 2026, representing cash available after capex. This represents an increase of 243.8% from the same quarter a year earlier. Against the prior quarter it is up 558.3%.

Cash & Debt

$239.0M

YoY-33.4%

QoQ+25.8%

5Y CAGR-6.4%

10Y CAGR-2.6%

DENTSPLY SIRONA Inc. held $239.0M in cash against $2.0B in long-term debt as of Q2 2026.

Shares Outstanding

199M

YoY-0.1%

QoQ-0.5%

DENTSPLY SIRONA Inc. had 199M shares outstanding in Q2 2026. This represents a decrease of 0.1% from the same quarter a year earlier. Against the prior quarter it is down 0.5%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

54.9%

YoY+2.6pp

QoQ+6.4pp

5Y change-1.1pp

10Y change+3.3pp

DENTSPLY SIRONA Inc.'s gross margin was 54.9% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 2.6 percentage points from the same quarter a year earlier. Against the prior quarter it is up 6.4 percentage points.

Operating Margin

9.1%

YoY+22.8pp

QoQ+13.1pp

5Y change-5.4pp

10Y change-2.7pp

DENTSPLY SIRONA Inc.'s operating margin was 9.1% in Q2 2026, reflecting core business profitability. This is up 22.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 13.1 percentage points.

Net Margin

4.1%

YoY+8.9pp

QoQ+5.3pp

5Y change-4.9pp

10Y change-6.2pp

DENTSPLY SIRONA Inc.'s net profit margin was 4.1% in Q2 2026, showing the share of revenue converted to profit. This is up 8.9 percentage points from the same quarter a year earlier. Against the prior quarter it is up 5.3 percentage points.

Return on Equity

2.7%

YoY+5.0pp

QoQ+3.5pp

5Y change+0.9pp

10Y change+1.5pp

DENTSPLY SIRONA Inc.'s ROE was 2.7% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 5.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 3.5 percentage points.

Capital Allocation

R&D Spending

$45.0M

YoY+21.6%

QoQ+2.3%

5Y CAGR+0.9%

DENTSPLY SIRONA Inc. invested $45.0M in research and development in Q2 2026. This represents an increase of 21.6% from the same quarter a year earlier. Against the prior quarter it is up 2.3%.

Capital Expenditures

$44.0M

YoY+37.5%

QoQ-15.4%

5Y CAGR+4.1%

10Y CAGR+5.0%

DENTSPLY SIRONA Inc. invested $44.0M in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 37.5% from the same quarter a year earlier. Against the prior quarter it is down 15.4%.

Share Buybacks

Not reported for Q2 2026.

XRAY Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

XRAY quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$3.6B	$3.7B-3.0%	$3.8B-4.3%	$4.0B+1.1%	$3.9B-7.3%	$4.2B+26.7%	$3.3B-17.0%	$4.0B+0.9%	$4.0B-0.2%	$4.0B+6.6%	$3.7B+40.0%	$2.7B-8.5%	$2.9B-1.0%	$3.0B+0.8%	$2.9B+15.4%	$2.5B
Cost of Revenue	$1.8B	$1.8B+0.3%	$1.8B-2.3%	$1.9B+4.7%	$1.8B-4.7%	$1.9B+11.9%	$1.7B-9.4%	$1.9B-3.1%	$1.9B+6.3%	$1.8B+3.5%	$1.7B+50.8%	$1.2B-12.5%	$1.3B-3.7%	$1.4B+0.1%	$1.4B+8.5%	$1.3B
Gross Profit	$1.8B	$1.8B-6.0%	$2.0B-6.1%	$2.1B-1.9%	$2.1B-9.4%	$2.3B+41.7%	$1.7B-23.5%	$2.2B+4.6%	$2.1B-5.5%	$2.2B+9.4%	$2.0B+31.9%	$1.5B-5.2%	$1.6B+1.4%	$1.6B+1.4%	$1.6B+22.2%	$1.3B
R&D Expenses	$166.0M	$150.0M-9.1%	$165.0M-10.3%	$184.0M+5.7%	$174.0M+1.8%	$171.0M+39.0%	$123.0M-14.0%	$143.0M-11.2%	$161.0M+6.1%	$151.7M+18.1%	$128.5M+71.6%	$74.9M-7.3%	$80.8M-5.1%	$85.1M-0.4%	$85.4M0.0%	$85.4M
SG&A Expenses	$1.5B	$1.4B-10.4%	$1.6B-0.5%	$1.6B+1.5%	$1.6B+2.5%	$1.6B+19.1%	$1.3B-18.0%	$1.6B-7.7%	$1.7B+2.6%	$1.7B+10.0%	$1.5B+41.4%	$1.1B-5.8%	$1.1B-0.1%	$1.1B-0.3%	$1.1B+22.6%	$936.8M
Operating Income	-$310.0M	-$422.0M+52.0%	-$879.0M-934.1%	-$85.0M+90.9%	-$937.0M-254.1%	$608.0M+20366.7%	-$3.0M-100.8%	$353.0M+136.8%	-$958.0M+38.7%	-$1.6B-443.6%	$454.7M+21.2%	$375.2M-15.8%	$445.6M+6.3%	$419.2M+9.8%	$381.9M+27.0%	$300.7M
EBITDA	N/A	-$70.0M+86.8%	-$530.0M-305.4%	$258.0M+142.4%	-$609.0M-163.8%	$955.0M+188.5%	$331.0M-51.0%	$676.0M+207.8%	-$627.0M+49.7%	-$1.2B-271.5%	$726.4M+45.8%	$498.1M-13.3%	$574.7M+5.0%	$547.1M+7.0%	$511.1M+32.5%	$385.8M
Interest Expense	$91.0M	$88.0M+27.5%	$69.0M-14.8%	$81.0M+24.6%	$65.0M+6.6%	$61.0M+27.1%	$48.0M+60.0%	$30.0M-18.9%	$37.0M-3.4%	$38.3M+6.7%	$35.9M-35.8%	$55.9M+19.2%	$46.9M-5.4%	$49.6M-12.8%	$56.9M+29.8%	$43.8M
Income Tax	$200.0M	$112.0M+530.8%	-$26.0M+39.5%	-$43.0M+59.0%	-$105.0M-178.4%	$134.0M+482.6%	$23.0M-72.0%	$82.0M+54.7%	$53.0M+199.6%	-$53.2M-660.0%	$9.5M-87.7%	$77.0M-5.1%	$81.1M+55.4%	$52.2M+485.2%	$8.9M-19.0%	$11.0M
Net Income	-$546.0M	-$598.0M+34.3%	-$910.0M-589.4%	-$132.0M+86.1%	-$950.0M-331.1%	$411.0M+663.0%	-$73.0M-128.5%	$256.0M+125.3%	-$1.0B+34.8%	-$1.6B-460.5%	$429.9M+71.1%	$251.2M-22.2%	$322.9M+3.1%	$313.2M-0.3%	$314.2M+28.5%	$244.5M
EPS (Basic)	N/A	-$3.00+33.0%	-$4.48-622.6%	-$0.62+85.9%	-$4.41-334.6%	$1.88+669.7%	-$0.33-128.7%	$1.15+125.5%	-$4.51+33.3%	-$6.76-443.1%	$1.97+10.1%	$1.79-21.5%	$2.28+3.6%	$2.20-0.9%	$2.22+28.3%	$1.73
EPS (Diluted)	-$2.74	-$3.00+33.0%	-$4.48-622.6%	-$0.62+85.9%	-$4.41-335.8%	$1.87+666.7%	-$0.33-128.9%	$1.14+125.3%	-$4.51+33.3%	-$6.76-448.5%	$1.94	$1.76-21.4%	$2.24+3.7%	$2.16-0.9%	$2.18+28.2%	$1.70
Diluted Shares (Avg)	N/A	199M-1.9%	203M-4.2%	212M-1.6%	216M-2.1%	220M+0.5%	219M-2.3%	224M0.0%	224M-2.2%	229M+3.5%	222M	143M-1.2%	144M-0.6%	145M+0.7%	144M+0.3%	144M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$898.0M-4.1%	$880.0M+0.1%	$961.0M+6.2%	$904.0M-4.9%	$936.0M-4.9%	$879.0M-7.8%	$905.0M-10.6%	$951.0M+0.4%
Cost of Revenue	$405.0M-9.2%	$453.0M+9.7%	$518.0M+12.9%	$463.0M+1.5%	$446.0M-5.7%	$413.0M-7.6%	$459.0M-6.3%	$456.0M+0.9%
Gross Profit	$493.0M+0.6%	$427.0M-8.4%	$443.0M-0.7%	$441.0M-10.9%	$490.0M-4.1%	$466.0M-7.9%	$446.0M-14.6%	$495.0M0.0%
R&D Expenses	$45.0M+21.6%	$44.0M+22.2%	$40.0M-4.8%	$37.0M-7.5%	$37.0M-9.8%	$36.0M-14.3%	$42.0M-2.3%	$40.0M-13.0%
SG&A Expenses	$364.0M+6.4%	$351.0M-2.0%	$383.0M-4.5%	$355.0M-9.0%	$342.0M-14.3%	$358.0M-13.7%	$401.0M-2.0%	$390.0M+4.8%
Operating Income	$82.0M+164.1%	-$35.0M-155.6%	-$139.0M+72.7%	-$218.0M+52.8%	-$128.0M-356.0%	$63.0M+50.0%	-$509.0M-797.3%	-$462.0M-95.8%
EBITDA	$167.0M+517.5%	$44.0M-69.0%	-$46.0M+89.1%	-$126.0M+66.2%	-$40.0M-129.4%	$142.0M+10.9%	-$421.0M-366.5%	-$373.0M-152.0%
Interest Expense	$22.0M-8.3%	$24.0M+26.3%	$22.0M+37.5%	$23.0M+27.8%	$24.0M+41.2%	$19.0M+5.6%	$16.0M-27.3%	$18.0M0.0%
Income Tax	$36.0M+133.0%	-$32.0M-228.0%	-$2.0M+97.9%	$198.0M+1064.7%	-$109.0M-386.8%	$25.0M+78.6%	-$95.0M-533.3%	$17.0M+6.3%
Net Income	$37.0M+182.2%	-$10.0M-150.0%	-$146.0M+66.0%	-$427.0M+13.6%	-$45.0M-1025.0%	$20.0M+11.1%	-$430.0M-741.8%	-$494.0M-85.7%
EPS (Basic)	$0.18+181.8%	-$0.05-150.0%	-$0.73+65.7%	-$2.14+13.0%	-$0.22-1000.0%	$0.10+11.1%	-$2.13-765.6%	-$2.46-96.8%
EPS (Diluted)	$0.18+181.8%	-$0.05-150.0%	-$0.73+65.7%	-$2.14+13.0%	-$0.22-1000.0%	$0.10+11.1%	-$2.13-765.6%	-$2.46-96.8%
Diluted Shares (Avg)	201M+0.6%	200M+0.1%	N/A	200M-0.7%	199M-3.1%	200M-4.2%	N/A	201M-5.1%

XRAY Balance Sheet

XRAY quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$5.4B-5.6%	$5.8B-21.9%	$7.4B-3.6%	$7.6B-17.3%	$9.2B-1.2%	$9.3B+8.7%	$8.6B-1.0%	$8.7B-16.3%	$10.4B-10.2%	$11.6B+162.5%	$4.4B-5.2%	$4.6B-8.4%	$5.1B+2.0%	$5.0B+4.6%	$4.8B
Current Assets	$2.0B+15.9%	$1.7B-11.5%	$2.0B+4.2%	$1.9B+2.2%	$1.9B+3.0%	$1.8B-10.1%	$2.0B+5.9%	$1.9B-5.7%	$2.0B+14.9%	$1.7B+45.7%	$1.2B-0.9%	$1.2B+5.5%	$1.1B+2.9%	$1.1B+9.7%	$1.0B
Cash & Equivalents	$326.0M+19.9%	$272.0M-18.6%	$334.0M-8.5%	$365.0M+7.7%	$339.0M-22.6%	$438.0M+8.1%	$405.0M+30.8%	$309.6M-3.4%	$320.6M-16.5%	$383.9M+34.9%	$284.6M+87.7%	$151.6M+102.1%	$75.0M-6.4%	$80.1M+3.9%	$77.1M
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$642.0M+13.8%	$564.0M-9.6%	$624.0M-0.5%	$627.0M+21.7%	$515.0M+8.2%	$476.0M-15.3%	$562.0M-6.2%	$598.9M-3.9%	$623.1M+20.5%	$517.1M+51.9%	$340.4M-12.1%	$387.1M-11.7%	$438.6M+8.8%	$402.9M+11.4%	$361.8M
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$1.1B-28.1%	$1.6B-34.5%	$2.4B-9.3%	$2.7B-32.4%	$4.0B-0.3%	$4.0B+17.3%	$3.4B-1.0%	$3.4B-24.4%	$4.5B-23.7%	$6.0B+199.5%	$2.0B-4.9%	$2.1B-8.4%	$2.3B+3.2%	$2.2B+1.0%	$2.2B
Total Liabilities	$4.1B+7.3%	$3.8B-6.5%	$4.1B+6.4%	$3.8B-9.7%	$4.2B-3.9%	$4.4B+25.9%	$3.5B-1.3%	$3.6B-5.1%	$3.7B+9.2%	$3.4B+66.2%	$2.1B-11.2%	$2.3B-6.9%	$2.5B-8.3%	$2.7B-5.2%	$2.9B
Current Liabilities	$1.3B-15.5%	$1.6B+11.5%	$1.4B+21.8%	$1.2B-7.2%	$1.3B-8.1%	$1.4B+37.9%	$995.0M-1.8%	$1.0B+6.2%	$954.5M+24.3%	$767.6M+61.3%	$476.0M-27.1%	$652.6M-17.8%	$793.8M-14.4%	$927.8M+28.1%	$724.1M
Non-Current Liabilities	$2.7B+23.6%	$2.2B-16.2%	$2.7B-0.4%	$2.7B-10.7%	$3.0B-2.0%	$3.0B+21.1%	$2.5B-1.1%	$2.5B-9.0%	$2.8B+4.9%	$2.7B+67.7%	$1.6B-5.0%	$1.7B-1.8%	$1.7B-5.2%	$1.8B-16.4%	$2.1B
Long-Term Debt	$2.0B+27.0%	$1.6B-11.7%	$1.8B-1.6%	$1.8B-4.5%	$1.9B-3.3%	$2.0B+38.0%	$1.4B-8.4%	$1.6B-2.9%	$1.6B+6.7%	$1.5B+32.4%	$1.1B-0.8%	$1.2B-1.2%	$1.2B-4.7%	$1.2B-18.0%	$1.5B
Total Equity	$1.3B-31.1%	$1.9B-41.0%	$3.3B-13.6%	$3.8B-23.7%	$5.0B+1.3%	$4.9B-3.2%	$5.1B-0.5%	$5.1B-22.6%	$6.6B-18.5%	$8.1B+247.1%	$2.3B+0.7%	$2.3B-8.4%	$2.5B+14.8%	$2.2B+19.5%	$1.8B
Retained Earnings	-$1.6B-87.3%	-$835.0M-507.3%	$205.0M-55.0%	$456.0M-69.9%	$1.5B+26.4%	$1.2B-14.7%	$1.4B+14.5%	$1.2B-47.1%	$2.3B-41.3%	$3.9B+9.9%	$3.6B+6.2%	$3.4B+9.2%	$3.1B+9.8%	$2.8B+11.2%	$2.5B

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$5.2B-14.3%	$5.2B-13.6%	$5.4B-5.6%	$5.7B-14.7%	$6.1B-12.0%	$6.0B-15.1%	$5.8B-21.9%	$6.6B-8.0%
Current Assets	$1.9B-1.9%	$1.8B-6.7%	$2.0B+15.9%	$2.1B+7.9%	$2.0B+11.8%	$2.0B+4.0%	$1.7B-11.5%	$1.9B+0.4%
Cash & Equivalents	$239.0M-33.4%	$190.0M-52.3%	$326.0M+19.9%	$363.0M+22.6%	$359.0M+28.7%	$398.0M+36.8%	$272.0M-18.6%	$296.0M-4.2%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$665.0M-1.5%	$659.0M+7.7%	$642.0M+13.8%	$686.0M+10.8%	$675.0M+11.0%	$612.0M-0.2%	$564.0M-9.6%	$619.0M-4.9%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$1.1B-25.5%	$1.1B-30.0%	$1.1B-28.1%	$1.3B-34.4%	$1.5B-36.0%	$1.6B-32.0%	$1.6B-34.5%	$1.9B-18.4%
Total Liabilities	$3.9B-6.2%	$3.9B-3.2%	$4.1B+7.3%	$4.2B+0.9%	$4.1B+7.2%	$4.0B+4.5%	$3.8B-6.5%	$4.1B+8.0%
Current Liabilities	$1.2B+1.6%	$1.2B-32.7%	$1.3B-15.5%	$1.4B-8.9%	$1.2B-11.9%	$1.8B+34.8%	$1.6B+11.5%	$1.5B+26.6%
Non-Current Liabilities	$2.7B-9.3%	$2.7B+20.3%	$2.7B+23.6%	$2.8B+6.8%	$2.9B+17.2%	$2.2B-11.4%	$2.2B-16.2%	$2.6B-0.7%
Long-Term Debt	$2.0B-10.0%	$2.0B+25.9%	$2.0B+27.0%	$2.0B+12.4%	$2.2B+27.7%	$1.6B-8.8%	$1.6B-11.7%	$1.8B-0.4%
Total Equity	$1.4B-31.1%	$1.3B-34.4%	$1.3B-31.1%	$1.5B-40.7%	$2.0B-36.0%	$2.0B-38.3%	$1.9B-41.0%	$2.5B-26.2%
Retained Earnings	-$1.5B-66.2%	-$1.6B-85.6%	-$1.6B-87.3%	-$1.4B-270.3%	-$925.0M-708.6%	-$848.0M-546.3%	-$835.0M-507.3%	-$374.0M-324.0%

Not reported in any period shown, so not listed: Accounts Receivable.

XRAY Cash Flow Statement

XRAY quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	$319.0M	$235.0M-49.0%	$461.0M+22.3%	$377.0M-27.1%	$517.0M-21.3%	$657.0M+1.2%	$649.0M+1.6%	$639.0M+27.8%	$500.0M-16.9%	$601.9M+6.8%	$563.4M+13.3%	$497.4M-11.2%	$560.4M+34.1%	$417.8M+13.0%	$369.7M-6.0%	$393.5M
Depreciation & Amortization	N/A	$352.0M+0.9%	$349.0M+1.7%	$343.0M+4.6%	$328.0M-5.5%	$347.0M+3.9%	$334.0M+3.4%	$323.0M-2.4%	$331.0M+4.6%	$316.4M+16.5%	$271.7M+121.1%	$122.9M-4.8%	$129.1M+0.9%	$127.9M-1.0%	$129.2M+51.9%	$85.0M
Stock-Based Compensation	N/A	$33.0M-15.4%	$39.0M-15.2%	$46.0M-22.0%	$59.0M+22.9%	$48.0M+2.1%	$47.0M-28.8%	$66.0M+214.3%	$21.0M-56.3%	$48.0M+16.2%	$41.3M+61.3%	$25.6M+0.8%	$25.4M+1.2%	$25.1M+13.1%	$22.2M+5.9%	$20.9M
Capital Expenditures	$176.0M	$131.0M-27.2%	$180.0M+20.8%	$149.0M0.0%	$149.0M+4.9%	$142.0M+63.2%	$87.0M-29.3%	$123.0M-32.8%	$183.0M+26.8%	$144.3M+15.4%	$125.0M+73.6%	$72.0M-27.7%	$99.6M-0.7%	$100.3M+8.9%	$92.1M+29.3%	$71.2M
Free Cash Flow	$143.0M	$104.0M-63.0%	$281.0M+23.2%	$228.0M-38.0%	$368.0M-28.5%	$515.0M-8.4%	$562.0M+8.9%	$516.0M+62.8%	$317.0M-30.7%	$457.6M+4.4%	$438.4M+3.1%	$425.4M-7.7%	$460.8M+45.1%	$317.5M+14.4%	$277.6M-13.9%	$322.3M
Investing Cash Flow	-$173.0M	-$132.0M+33.0%	-$197.0M-121.3%	-$89.0M+35.5%	-$138.0M+61.5%	-$358.0M+67.6%	-$1.1B-1502.9%	-$69.0M+72.7%	-$253.0M+11.7%	-$286.4M-577.3%	$60.0M+209.3%	-$54.9M+60.4%	-$138.7M+46.7%	-$260.2M-126.2%	-$115.0M+93.9%	-$1.9B
Financing Cash Flow	-$265.0M	-$80.0M+73.5%	-$302.0M+1.6%	-$307.0M+6.7%	-$329.0M+13.2%	-$379.0M-179.6%	$476.0M+200.8%	-$472.0M-88.8%	-$250.0M+37.6%	-$400.8M+23.8%	-$526.2M-73.7%	-$302.9M+9.9%	-$336.2M-107.9%	-$161.7M+36.7%	-$255.6M-125.5%	$1.0B
Dividends Paid	$96.0M	$128.0M+1.6%	$126.0M+8.6%	$116.0M+11.5%	$104.0M+13.0%	$92.0M+4.5%	$88.0M+8.6%	$81.0M+2.5%	$79.0M+0.9%	$78.3M+21.2%	$64.6M+61.5%	$40.0M+7.2%	$37.3M+7.2%	$34.8M+10.7%	$31.4M+9.8%	$28.6M
Share Buybacks	N/A	$0-100.0%	$250.0M-16.7%	$300.0M+100.0%	$150.0M-25.0%	$200.0M+42.9%	$140.0M-46.2%	$260.0M+4.0%	$250.0M-37.7%	$401.4M-50.7%	$813.9M+622.2%	$112.7M-30.9%	$163.2M+38.3%	$118.0M+203.8%	$38.8M-51.1%	$79.5M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	$99.0M+106.3%	$40.0M+471.4%	$101.0M+16.1%	$79.0M-44.0%	$48.0M-76.9%	$7.0M-72.0%	$87.0M-45.6%	$141.0M+5.2%
Depreciation & Amortization	$85.0M-3.4%	$79.0M0.0%	$93.0M+5.7%	$92.0M+3.4%	$88.0M+2.3%	$79.0M-8.1%	$88.0M+3.5%	$89.0M+1.1%
Stock-Based Compensation	$9.0M0.0%	$8.0M-20.0%	N/A	$6.0M-50.0%	$9.0M-25.0%	$10.0M-9.1%	N/A	$12.0M+500.0%
Capital Expenditures	$44.0M+37.5%	$52.0M+173.7%	$41.0M-19.6%	$39.0M-9.3%	$32.0M-38.5%	$19.0M-44.1%	$51.0M+27.5%	$43.0M+16.2%
Free Cash Flow	$55.0M+243.8%	-$12.0M0.0%	$60.0M+66.7%	$40.0M-59.2%	$16.0M-89.7%	-$12.0M-33.3%	$36.0M-70.0%	$98.0M+1.0%
Investing Cash Flow	-$39.0M-14.7%	-$53.0M-211.8%	-$45.0M+21.1%	-$36.0M+23.4%	-$34.0M+32.0%	-$17.0M+60.5%	-$57.0M-185.0%	-$47.0M-2250.0%
Financing Cash Flow	-$11.0M+83.8%	-$119.0M-196.7%	-$99.0M-160.5%	-$36.0M+54.4%	-$68.0M+60.2%	$123.0M+978.6%	-$38.0M+70.3%	-$79.0M+27.5%
Dividends Paid	$0-100.0%	$32.0M0.0%	$32.0M+3.2%	$32.0M-3.0%	$32.0M-3.0%	$32.0M+10.3%	$31.0M+3.3%	$33.0M+13.8%
Share Buybacks	N/A	N/A	$0	$0-100.0%	N/A	N/A	$0-100.0%	$100.0M

XRAY Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

XRAY quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	50.0%-1.6pp	51.6%-1.0pp	52.6%-1.6pp	54.2%-1.2pp	55.5%+5.9pp	49.6%-4.2pp	53.8%+1.9pp	51.9%-2.9pp	54.8%+1.4pp	53.4%-3.3pp	56.7%+2.0pp	54.7%+1.3pp	53.5%+0.3pp	53.1%+3.0pp	50.2%
Operating Margin	-11.5%+11.7pp	-23.2%-21.0pp	-2.1%+21.8pp	-23.9%-38.3pp	14.4%+14.5pp	-0.1%-8.9pp	8.8%+32.8pp	-24.0%+15.1pp	-39.1%-51.3pp	12.1%-1.9pp	14.0%-1.2pp	15.3%+1.0pp	14.2%+1.2pp	13.0%+1.2pp	11.8%
Net Margin	-16.3%+7.7pp	-24.0%-20.7pp	-3.3%+20.9pp	-24.2%-33.9pp	9.7%+11.9pp	-2.2%-8.6pp	6.4%+31.7pp	-25.4%+13.5pp	-38.8%-50.3pp	11.5%+2.1pp	9.4%-1.7pp	11.1%+0.4pp	10.6%-0.1pp	10.7%+1.1pp	9.6%
Return on Equity	-44.7%+2.2pp	-46.9%-42.9pp	-4.0%+20.9pp	-24.9%-33.2pp	8.2%+9.7pp	-1.5%-6.5pp	5.0%+24.8pp	-19.7%+3.7pp	-23.4%-28.7pp	5.3%-5.4pp	10.7%-3.2pp	13.9%+1.6pp	12.3%-1.9pp	14.2%+1.0pp	13.2%
Return on Assets	-11.0%+4.8pp	-15.8%-14.0pp	-1.8%+10.6pp	-12.4%-16.9pp	4.5%+5.2pp	-0.8%-3.8pp	3.0%+14.6pp	-11.6%+3.3pp	-14.9%-18.7pp	3.7%-2.0pp	5.7%-1.2pp	7.0%+0.8pp	6.2%-0.2pp	6.3%+1.2pp	5.1%
Current Ratio	1.51+0.4x	1.10-0.3x	1.38-0.2x	1.62+0.1x	1.47+0.2x	1.31-0.7x	2.01+0.1x	1.86-0.2x	2.10-0.2x	2.27-0.2x	2.51+0.7x	1.85+0.4x	1.44+0.2x	1.20-0.2x	1.40
Debt-to-Equity	1.50+0.7x	0.82+0.3x	0.55+0.1x	0.48+0.1x	0.380.0x	0.40+0.1x	0.280.0x	0.31+0.1x	0.24+0.1x	0.19-0.3x	0.490.0x	0.500.0x	0.46-0.1x	0.55-0.3x	0.81
Asset Turnover	0.680.0x	0.66+0.1x	0.540.0x	0.51+0.1x	0.46+0.1x	0.36-0.1x	0.470.0x	0.46+0.1x	0.38+0.1x	0.32-0.3x	0.610.0x	0.630.0x	0.580.0x	0.59+0.1x	0.53
FCF Margin	2.8%-4.6pp	7.4%+1.7pp	5.8%-3.6pp	9.4%-2.8pp	12.2%-4.7pp	16.8%+4.0pp	12.8%+4.9pp	8.0%-3.5pp	11.5%-0.3pp	11.7%-4.2pp	15.9%+0.1pp	15.8%+5.0pp	10.8%+1.3pp	9.5%-3.2pp	12.7%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	54.9%+2.6pp	48.5%-4.5pp	46.1%-3.2pp	48.8%-3.3pp	52.3%+0.4pp	53.0%-0.1pp	49.3%-2.3pp	52.0%-0.2pp
Operating Margin	9.1%+22.8pp	-4.0%-11.2pp	-14.5%+41.8pp	-24.1%+24.5pp	-13.7%-18.8pp	7.2%+2.8pp	-56.2%-63.5pp	-48.6%-23.7pp
Net Margin	4.1%+8.9pp	-1.1%-3.4pp	-15.2%+32.3pp	-47.2%+4.7pp	-4.8%-4.4pp	2.3%+0.4pp	-47.5%-54.1pp	-51.9%-23.9pp
Return on Equity	2.7%+5.0pp	-0.8%-1.8pp	-10.9%+11.2pp	-28.9%-9.1pp	-2.3%-2.2pp	1.0%+0.5pp	-22.1%-24.2pp	-19.8%-12.0pp
Return on Assets	0.7%+1.5pp	-0.2%-0.5pp	-2.7%+4.8pp	-7.5%-0.1pp	-0.7%-0.7pp	0.3%+0.1pp	-7.5%-8.4pp	-7.5%-3.8pp
Current Ratio	1.63-0.1x	1.53+0.4x	1.51+0.4x	1.47+0.2x	1.69+0.4x	1.10-0.3x	1.10-0.3x	1.25-0.3x
Debt-to-Equity	1.48+0.3x	1.52+0.7x	1.50+0.7x	1.36+0.6x	1.13+0.6x	0.79+0.3x	0.82+0.3x	0.72+0.2x
Asset Turnover	0.170.0x	0.170.0x	0.180.0x	0.160.0x	0.150.0x	0.150.0x	0.160.0x	0.140.0x
FCF Margin	6.1%+4.4pp	-1.4%0.0pp	6.2%+2.3pp	4.4%-5.9pp	1.7%-14.1pp	-1.4%-0.4pp	4.0%-7.9pp	10.3%+0.1pp

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
DENTSPLY SIRONA Inc. XRAY	FY2025	$3.7B	-$598.0M	-16.3%	$1.7B	30/100
Envista Holdings Corporation NVST	FY2025	$2.7B	$47.0M	1.7%	$3.8B	43/100
Warby Parker Inc. WRBY	FY2025	$871.9M	$1.6M	0.2%	$3.3B	48/100
LeMaitre Vascular, Inc. LMAT	FY2025	$249.6M	$57.7M	23.1%	$1.8B	81/100
ICU Medical Inc ICUI	FY2025	$2.2B	$732K	0.0%	$4.0B	36/100
Merit Medical Systems Inc MMSI	FY2025	$1.5B	$128.5M	8.5%	$5.1B	69/100

Where DENTSPLY SIRONA Inc. Ranks

Frequently Asked Questions

What is DENTSPLY SIRONA Inc.'s annual revenue?

DENTSPLY SIRONA Inc. (XRAY) reported $3.7B in total revenue for fiscal year 2025. This represents a -3.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is DENTSPLY SIRONA Inc.'s revenue growing?

DENTSPLY SIRONA Inc. (XRAY) revenue declined by 3.0% year-over-year, from $3.8B to $3.7B in fiscal year 2025.

Is DENTSPLY SIRONA Inc. profitable?

No, DENTSPLY SIRONA Inc. (XRAY) reported a net income of -$598.0M in fiscal year 2025, with a net profit margin of -16.3%.

What is DENTSPLY SIRONA Inc.'s EBITDA?

DENTSPLY SIRONA Inc. (XRAY) had EBITDA of -$70.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does DENTSPLY SIRONA Inc. have?

As of fiscal year 2025, DENTSPLY SIRONA Inc. (XRAY) had $326.0M in cash and equivalents against $2.0B in long-term debt.

What is DENTSPLY SIRONA Inc.'s gross margin?

DENTSPLY SIRONA Inc. (XRAY) had a gross margin of 50.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is DENTSPLY SIRONA Inc.'s operating margin?

DENTSPLY SIRONA Inc. (XRAY) had an operating margin of -11.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is DENTSPLY SIRONA Inc.'s net profit margin?

DENTSPLY SIRONA Inc. (XRAY) had a net profit margin of -16.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Does DENTSPLY SIRONA Inc. pay dividends?

Yes, DENTSPLY SIRONA Inc. (XRAY) paid $0.64 per share in dividends during fiscal year 2025.

What is DENTSPLY SIRONA Inc.'s return on equity (ROE)?

DENTSPLY SIRONA Inc. (XRAY) has a return on equity of -44.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is DENTSPLY SIRONA Inc.'s free cash flow?

DENTSPLY SIRONA Inc. (XRAY) generated $104.0M in free cash flow during fiscal year 2025. This represents a -63.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is DENTSPLY SIRONA Inc.'s operating cash flow?

DENTSPLY SIRONA Inc. (XRAY) generated $235.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are DENTSPLY SIRONA Inc.'s total assets?

DENTSPLY SIRONA Inc. (XRAY) had $5.4B in total assets as of fiscal year 2025, including both current and long-term assets.

What are DENTSPLY SIRONA Inc.'s capital expenditures?

DENTSPLY SIRONA Inc. (XRAY) invested $131.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does DENTSPLY SIRONA Inc. spend on research and development?

DENTSPLY SIRONA Inc. (XRAY) invested $150.0M in research and development during fiscal year 2025.

How many shares does DENTSPLY SIRONA Inc. have outstanding?

DENTSPLY SIRONA Inc. (XRAY) had 200M shares outstanding as of fiscal year 2025.

What is DENTSPLY SIRONA Inc.'s current ratio?

DENTSPLY SIRONA Inc. (XRAY) had a current ratio of 1.51 as of fiscal year 2025, which is generally considered healthy.

What is DENTSPLY SIRONA Inc.'s debt-to-equity ratio?

DENTSPLY SIRONA Inc. (XRAY) had a debt-to-equity ratio of 1.50 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is DENTSPLY SIRONA Inc.'s return on assets (ROA)?

DENTSPLY SIRONA Inc. (XRAY) had a return on assets of -11.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is DENTSPLY SIRONA Inc.'s P/E ratio?

DENTSPLY SIRONA Inc. (XRAY) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $1.7B as of Oct 5, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is DENTSPLY SIRONA Inc.'s price-to-sales ratio?

DENTSPLY SIRONA Inc. (XRAY) trades at 0.5x sales, its market capitalization divided by revenue of $3.6B revenue, trailing 12 months to June 30, 2026. The market capitalization is $1.7B as of Oct 5, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is DENTSPLY SIRONA Inc.'s Altman Z-Score?

DENTSPLY SIRONA Inc. (XRAY) has an Altman Z-Score of 0.42, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is DENTSPLY SIRONA Inc.'s Piotroski F-Score?

DENTSPLY SIRONA Inc. (XRAY) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are DENTSPLY SIRONA Inc.'s earnings high quality?

DENTSPLY SIRONA Inc. (XRAY) reported a net loss of $598.0M while generating $235.0M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can DENTSPLY SIRONA Inc. cover its interest payments?

DENTSPLY SIRONA Inc. (XRAY) reported an operating loss of $422.0M against $88.0M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is DENTSPLY SIRONA Inc.?

DENTSPLY SIRONA Inc. (XRAY) scores 30 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.